Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells (2025)

Peer-Reviewed Study · Morinaga S; Han Q; Mizuta K; Kang BM; et al. · 2025

Morinaga S et al., 2025: In vitro study working with an ivermectin-resistant MCF-7 subline and reporting that methionine restriction with rMETase re-sensitises those cells, i.e. breast cancer cells can become ivermectin-resistant and single-agent ivermectin has limited potency.

MCF-7 cells were treated with four groups: untreated control; ivermectin alone (4.89 μM, IC10); rMETase alone (2.75 U/ml,

n/a (PubMed abstract)

Morinaga S et al., 2025: In vitro study working with an ivermectin-resistant MCF-7 subline and reporting that methionine restriction with rMETase re-sensitises those cells, i.e. breast cancer cells can become ivermectin-resistant and single-agent ivermectin has limited potency. Study type: MCF-7 breast cancer cells in vitro, including an ivermectin-resistant derivative. N: n/a. Country: USA (AntiCancer Inc., San Diego). Dose: ivermectin at its IC10 of 4.89 uM in this line. DECLARED COI / BUSINESS TIE: all authors are at AntiCancer Inc., the company developing rMETase, which is the combination agent being promoted – recorded as neutral disclosure. Comparator: untreated, ivermectin alone, rMETase alone. Excerpt is a methods record field and ends mid-sentence; confidence MEDIUM for that reason. Study type: lab.